Menu

CME Corner

Program Detail

Release Date: January-26-18
Credit Expiration Date: January-26-19

Faculty

Andrew McGinnitie, MD, PhD
Clinical Director, Division of Immunology
Boston Children's Hospital
Assistant Professor of Pediatrics
Harvard Medical School
Boston, MA 

Kenan Haver, MD
Director, Pulmonary Division Asthma Center
Boston Children's Hospital
Assistant Professor of Pediatrics
Harvard Medical School
Boston, MA

CCME Reviewer
David L. Rosenstreich, MD 
Professor, Department of Medicine (Allergy & Immunology)
Chief, Division of Allergy & Immunology, Department of Medicine
Joseph and Sadie Danciger Distinguished Scholar in Microbiology/Immunology
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY 

Credit Hours

0.5

Medium

Online Presentation

Program Description

An evolving understanding of pediatric allergic asthma’s complex immunopathology is contributing to new treatment paradigms. This activity will examine the impact of asthma phenotypes and endotypes on treatment selection.

Program Developer/Facilitator

This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.

Target Audience

This educational activity is designed for allergists, pulmonologists, pediatricians, primary care physicians, and other clinicians involved in the diagnosis and management of allergic asthma in pediatric patients.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Characterize the role of phenotypes and endotypes in the management of pediatric asthma.
  2. Apply new and emerging pharmacologic treatments for the management of allergic asthma to clinical practice.

Disclosures

The Albert Einstein College of Medicine also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.

FACULTY DISCLOSURES

Andrew McGinnitie, MD, PhD
Nothing to disclose.

Kenan Haver, MD
Nothing to disclose.

David L. Rosenstreich, MD
Nothing to disclose.

The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests relative to this CME activity.

Scott Kober, Writer/Editor, MCM Education, has no conflicts of interest to disclose.
Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose.
Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education, has no conflicts of interest to disclose.

Credit Statements

ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Albert Einstein College of Medicine, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

This activity is supported by educational grants from GlaxoSmithKline and Novartis Pharmaceuticals.

Certificate Fee

$0.00

Disclaimer

Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, and MCM Education.

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, GlaxoSmithKline, or Novartis Pharmaceuticals. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS